Difficulties in Determining Carcinogenicity of Omeprazole
- Limited number of subjects followed for longer than 1 year
- Lack of long-term prospective or nested cohort studies to track patients
- Detection of malignancy - long lag phase
- High background rates of malignancies - drown out weak ‘signals’